Research progress of radiotherapy combined with EGFR-TKI in the treatment of brain metastasis from lung cancer
10.3760/cma.j.issn.1006-9801.2014.05.020
- VernacularTitle:同期放疗联合表皮生长因子受体-酪氨酸激酶抑制剂治疗非小细胞肺癌脑转移的研究进展
- Author:
Lijia YIN
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Neoplasm metastasis;
Radiotherapy;
EGFR-TKI
- From:
Cancer Research and Clinic
2014;26(5):351-353
- CountryChina
- Language:Chinese
-
Abstract:
Brain metastasis is a common and devastating consequence of disease progression in patients with lung cancer.Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) may enhance radiosensitivity by reducing the cells in S phase,reducing angiogenesis of tumor cells,increasing irradiation apoptosis,inhibiting tumor cells proliferation by fractionated irradiation and reducing radiotherapy resistance.The clinical results of radiotherapy combined with EGFR-TKI (such as gefitinib) in treatment of brain metastasis from lung cancer showed higher response rate and longer survival.The toxicities during EGFR-TKI treatments were low,and could be controllable after symptomatic treatment.Administration of EGFR-TKI combined radiotherapy conferred minimum influence on radiotherapy.
